Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 111 от 154

Активно (без набиране) Фаза 3

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study. Participants will be in the study for approximately 128 weeks. All participants will have the opportunity to receive intravenous (IV) delandistrogene moxeparvovec in either Part 1 or Part 2.

Начало: 31.05.2023 Край: 30.06.2028 Лечение

Australia, Belgium, Canada +11 Sarepta Therapeutics, Inc. NCT05881408

Активно (без набиране) Фаза 3

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients based upon the established epidemiology of the disease.

Начало: 31.05.2023 Край: 01.07.2027 Възраст: 12–60 г. Лечение

Australia, Denmark, Italy +4 ML Bio Solutions, Inc. NCT05775848

Активно (без набиране) Фаза 3

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Atopic Dermatitis

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Начало: 31.05.2023 Край: 30.06.2027 Възраст: 12–100 г. Лечение

Argentina, Australia, Belgium +35 Amgen NCT05882877

Активно (без набиране) Фаза 3

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC)

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Начало: 31.05.2023 Край: 26.03.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +25 Amgen NCT05740566

Активно (без набиране) Фаза 3

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Obesity Cardiovascular Diseases

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

Начало: 30.05.2023 Край: 01.05.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Canada +7 Eli Lilly and Company NCT05882045

Активно (без набиране) Фаза 3

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

C3G IC-MPGN C3 Glomerulopathy C3 Glomerulonephritis +8

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

Начало: 29.05.2023 Край: 01.07.2027 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +12 Apellis Pharmaceuticals, Inc. NCT05809531

Активно (без набиране) Фаза 2

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Cutaneous Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma of the Head and Neck Neoplasms Non-melanoma Skin Cancer

To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.

Начало: 26.05.2023 Край: 01.05.2029 Възраст: от 18 г. Друго

Australia Peter MacCallum Cancer Centre, Australia NCT05878288

Активно (без набиране) Фаза 2

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

HIV Infection

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection. The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN, TAB and ZAB, versus continuing on baseline oral antiretroviral therapy (ART) as determined by the proportion of participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) ≥ 50 copies/mL at Week 26.

Начало: 15.05.2023 Край: 01.12.2029 Възраст: 18–65 г. Лечение

Australia, Canada, Puerto Rico +1 Gilead Sciences NCT05729568

Активно (без набиране)

Ultra Low Frequency Spinal Cord Stimulation for Chronic Low Back Pain

Chronic Pain Chronic Low-back Pain

The Presidio Medical Ultra Low Frequency (ULF™) Spinal Cord Stimulation (SCS) System is intended to provide pain relief to participants who have been clinically diagnosed with chronic low back pain with or without leg pain.

Начало: 09.05.2023 Край: 01.03.2028 Възраст: от 18 г. Лечение

Australia Presidio Medical, Inc NCT05837234

Активно (без набиране) Фаза 3

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Locally Advanced or Unresectable Metastatic Breast Cancer Stage IV Breast Cancer

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).

Начало: 08.05.2023 Край: 01.04.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +23 Gilead Sciences NCT05840211

Активно (без набиране) Фаза 1

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia

SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

Начало: 02.05.2023 Край: 04.11.2038 Възраст: 18–80 г. Лечение

Australia, United States Sana Biotechnology NCT05878184

Активно (без набиране) Фаза 4

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Diabetic Macular Edema

This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.

Начало: 01.05.2023 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Canada, United Kingdom +1 McMaster University NCT05610319

Активно (без набиране) Фаза 1

Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults

SARS-CoV-2

Glycovax Pharma has developed a glycoconjugate vaccine candidate called Glycovax-002 to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the origin of COVID-19. The aim of the study is to assess the safety, reactogenicity and immunogenicity of Glycovax-002 in humans. The study is a phase I, placebo-controlled, dose-escalation study conducted in 36 healthy females and males aged between 18 and 55 years old. The vaccine will be administered three times with a two-week time interval between each dose. Dose escalation is conducted in three steps. At each step, 9 participants receiving the vaccine will be randomized with 3 participants receiving placebo (normal saline). Progression to next step is conditional to a DSMB's approval.

Начало: 28.04.2023 Край: 31.12.2024 Възраст: 18–55 г. Превенция

Australia Glycovax Pharma Inc. NCT05799651

Активно (без набиране) Фаза 2

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Locally Advanced Pancreatic Cancer

The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of Locally Advanced Pancreatic Cancer

Начало: 26.04.2023 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Italy +2 OncoSil Medical Limited NCT05466799

Активно (без набиране) Фаза 3

SODium BICarbonate for Metabolic Acidosis in the ICU

Metabolic Acidosis Shock

This trial aims to assess if, among adults in the ICU with metabolic acidosis, an infusion of sodium bicarbonate diluted in 5% dextrose, compared with an infusion of 5% dextrose, reduces Major Adverse Kidney Events within 30 days of randomization.

Начало: 26.04.2023 Край: 01.07.2026 Възраст: от 18 г. Лечение

Australia, Brazil, India +4 Australian and New Zealand Intensive Care Research Cent NCT05697770

Активно (без набиране) Фаза 2

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

Начало: 21.04.2023 Край: 31.10.2026 Възраст: от 18 г. Лечение

Australia, China, France +6 Hoffmann-La Roche NCT05805501

Активно (без набиране) Фаза 3

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Systemic Lupus Erythematosus

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).

Начало: 21.04.2023 Край: 09.04.2029 Възраст: 12–100 г. Лечение

Argentina, Australia, Chile +12 Novartis Pharmaceuticals NCT05624749

Активно (без набиране) Фаза 2

D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)

Major Depressive Disorder

The goal of this clinical trial is to investigate if the drug D-Cycloserine (DCS) improves the antidepressant effects of Intermittent Theta Burst Stimulation (iTBS), a non-invasive brain stimulation therapy, in patients with Major Depressive Disorder (MDD). The main questions it aims to answer are: * Whether taking DCS prior to iTBS therapy will be more effective in improving depressive symptoms than iTBS therapy alone. * Compare the effect of DCS 100mg/day versus 50mg/day on depressive symptoms. * Test the safety and tolerability of DCS. Participants will take either 50mg DCS per day, 100mg DCS or placebo prior to each iTBS treatment session. iTBS treatment will be administered daily, 5 days a week for 4 weeks. Clinical measures will be conducted at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.

Начало: 21.04.2023 Край: 29.05.2026 Възраст: от 18 г. Лечение

Australia The Alfred NCT05591677

Активно (без набиране)

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO

Extracorporeal Membrane Oxygenation Red Blood Cell Transfusion Organ Failure, Multiple

TITRE - Trial of Indication-based Transfusion of Red Blood Cells in ECMO, is a multicenter, prospective, randomized clinical trial. The overarching goal of TITRE is to determine whether restricting red blood cell (RBC) transfusion according to an indication-based strategy for those with bleeding and/or deficit of tissue oxygen delivery, compared with transfusion based on center-specific hemoglobin or hematocrit thresholds, can reduce organ dysfunction and improve later neurodevelopment in critically ill children receiving Extracorporeal Membrane Oxygenation (ECMO) support.

Начало: 14.04.2023 Край: 01.12.2026 Възраст: до 6 г. Друго

Australia, Canada, United States Boston Children's Hospital NCT05405426

Активно (без набиране) Фаза 2

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Urothelial Cancer

This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.

Начало: 13.04.2023 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Brazil, China +11 Hoffmann-La Roche NCT05645692

1 … 109 110 111 112 113 … 154